title: Tumor suppressors status in cancer cell line Encyclopedia.
abstract: Tumor suppressors play a major role in the etiology of human cancer, and typically achieve a tumor-promoting effect upon complete functional inactivation. Bi-allelic inactivation of tumor suppressors may occur through genetic mechanisms (such as loss of function mutation, copy number (CN) loss, or loss of heterozygosity (LOH)), epigenetic mechanisms (such as promoter methylation or histone modification), or a combination of the two. We report systematically derived status of 69 known or putative tumor suppressors, across 799 samples of the Cancer Cell Line Encyclopedia. In order to generate such resource we constructed a novel comprehensive computational framework for the assessment of tumor suppressor functional "status". This approach utilizes several orthogonal genomic data types, including mutation data, copy number, LOH and expression. Through correlation with additional data types (compound sensitivity and gene set activity) we show that this integrative method provides a more accurate assessment of tumor suppressor status than can be inferred by expression, copy number, or mutation alone. This approach has the potential for a more realistic assessment of tumor suppressor genes for both basic and translational oncology research.
authors: University of South Wales, Pontypridd, Wales, UK. dmitriy.sonkin@southwales.ac.uk
authors: Dmitriy
authors: D
authors: Sonkin
authors: Mehedi
authors: M
authors: Hassan
authors: Denis J
authors: DJ
authors: Murphy
authors: Tatiana V
authors: TV
authors: Tatarinova
mesh_terms: D045744:Cell Line, Tumor; D056915:DNA Copy Number Variations / Q000235:genetics; D019175:DNA Methylation / Q000235:genetics*; D044127:Epigenesis, Genetic / Q000235:genetics; D057890:Epigenomics; D006801:Humans; D019656:Loss of Heterozygosity / Q000235:genetics
keywords: CCLE; Cancer cell line; DNA methylation; Epigenetics; Loss of function; Tumor suppressor
references: Science. 2004 Feb 6;303(5659):844-8
references: 14704432
references: Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14
references: 22080510
references: BMC Bioinformatics. 2005 Jun 29;6:163
references: 15987529
references: Hum Mutat. 2007 Jun;28(6):622-9
references: 17311302
references: Annu Rev Genet. 1997;31:571-610
references: 9442908
references: Genes Dev. 2009 Mar 1;23(5):537-48
references: 19270154
references: Nat Rev Genet. 2002 Jun;3(6):415-28
references: 12042769
references: Annu Rev Genet. 1990;24:615-57
references: 2088179
references: Nat Genet. 2007 Dec;39(12):1522-7
references: 17982454
references: Nature. 2012 Mar 28;483(7391):603-7
references: 22460905
references: BMC Bioinformatics. 2005 Mar 17;6:58
references: 15774002
references: Nucleic Acids Res. 2001 Jan 1;29(1):308-11
references: 11125122
references: PLoS Comput Biol. 2008 Nov;4(11):e1000217
references: 18989396
references: Breast Cancer Res. 2009;11(5):R77
references: 19874578
references: J Pathol. 2010 Jan;220(2):164-73
references: 19918835
references: Cancer Res. 2007 Aug 1;67(15):7350-7
references: 17671205
references: Bioinformatics. 2011 Jun 15;27(12):1739-40
references: 21546393
references: Nature. 2001 May 17;411(6835):336-41
references: 11357140
references: Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
references: 5279523
references: Bioinformatics. 2002 Dec;18(12):1585-92
references: 12490442
references: Nature. 1997 May 15;387(6630):299-303
references: 9153396
references: PLoS One. 2009 Nov 18;4(11):e7887
references: 19924296
references: Nat Methods. 2008 Jul;5(7):621-8
references: 18516045
references: Eur J Cancer. 2002 May;38(7):867-71
references: 11978510
references: Mol Oncol. 2013 Aug;7(4):791-8
references: 23639312
references: Nat Biotechnol. 2011 Feb;29(2):117-8
references: 21301433
references: Carcinogenesis. 2005 Dec;26(12):2031-45
references: 16150895